$CELG (Celgene Corporation)

$CELG {{ '2017-04-27T12:06:27+0000' | timeago}} • Announcement

For 2017, $CELG expects total revenue to be $13-13.4Bil. Diluted EPS is expected to be $5.95-6.29 while adjusted diluted EPS is expected to be $7.15-7.30. Operating margin is expected to be approx. 46% while adjusted operating margin is expected to be 57%.

$CELG {{ '2017-10-20T12:40:12+0000' | timeago}} • Announcement

$CELG disclosed in an SEC filing that it expects to incur a pretax charge to earnings for 4Q17 in the range of $300-500MM ($0.27-0.45 per diluted share after tax) in connection with its decision to stop the two trials for Crohn's disease. Celgene also added that it would require to pay half of this charge in cash.

$CELG {{ '2017-10-19T21:12:44+0000' | timeago}} • Announcement

$CELG said that it will stop the two trials for treating the Crohn's disease (a chronic inflammatory bowel disease), following an recommendation of the Data Monitoring Committee. No safety signals were identified during a recent interim futility analysis. Celgene added that the third trial will not be initiated at this time.

$CELG {{ '2017-09-19T18:41:27+0000' | timeago}} • Announcement

After collaborating with $CELG for almost a decade, $XLRN amended its development and commercial agreement with Celgene for the investigational drug Sotatercept. Acceleron will develop and market Sotatercept in the pulmonary hypertension field. Celgene will be eligible to receive royalties on global net sales in that field.

$CELG {{ '2017-09-08T15:34:27+0000' | timeago}} • Announcement

$CELG to present data from multiple studies about the use of Abraxane to treat non-small lung cancer and pancreatic cancer. The data will be presented at the European Society of Medical Oncology (ESMO) 2017 Annual Meeting between Sept 8-12 in Madrid, Spain.

$CELG {{ '2017-09-07T15:10:29+0000' | timeago}} • Announcement

$CELG gets a pause from FDA as it partially holds the drugmaker's five clinical trials and one clinical trial fully. All of these trials involve cancer drug Durvalumab. Celgene added that patients enrolled in the partial hold trials may remain on the treatment and those who are on full clinical hold trial will be discontinued from the treatment.

$CELG {{ '2017-08-01T17:51:34+0000' | timeago}} • Announcement

$CELG and $AGIO said Idhifa (enasidenib) was granted approval from FDA for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 mutation. The approval was based on results from the Phase I/II study. AML is a cancer of blood and bone marrow marked by rapid disease progression.

$CELG {{ '2017-07-27T19:16:33+0000' | timeago}} • Announcement

For FY17, $CELG cut down its GAAP EPS outlook to $5.36-5.62 from its prior estimate of $5.95-6.29. However, Celgene lifted its non-GAAP EPS outlook to $7.25-7.35 from its previous estimate of $7.15-7.30. The company didn't alter its previous revenue outlook of $13.0-13.4Bil.

$CELG {{ '2017-07-27T18:53:16+0000' | timeago}} • Announcement

Biotech heavyweight $CELG reported strong profit in 2Q17, helped by higher product sales. Net income of $1.06Bil and diluted EPS of $1.31, surged 77% and 75%, respectively. Total revenue rose 19% to $3.3Bil, while  net product sales alos increased 19% for the recent quarter. Celgene's earnings grew 26% to $1.82 per share on an adjusted basis.

$CELG {{ '2017-07-27T14:01:16+0000' | timeago}} • Infographic

$CELG Celgene Earnings AlphaGraphic: Q2 2017 highlights

$CELG {{ '2017-07-25T20:43:29+0000' | timeago}} • Announcement

$CELG, which is set to release its earnings results on July 27, settles a lawsuit filed by Beverly Brown, a former saleswoman of the drugmaker, by paying a total of $280MM. The lawsuit claimed that Celgene used illegal marketing tactics to promote its cancer drugs Thalomid and Revlimid among doctors.

$CELG {{ '2017-07-06T14:11:20+0000' | timeago}} • Announcement

Upon closing of $CELG/$BGNE transaction, which is expected during 3Q17, BeiGene to receive upfront license fees of $263MM and $150MM in equity investment. BeiGene will also be eligible to receive up to $980MM in development, regulatory and sales milestone payments and royalties on future sales of BGB-A317, a drug used to treat cancers.

$CELG {{ '2017-07-06T14:08:05+0000' | timeago}} • Announcement

$CELG enters into a collaborative agreement with biopharma company $BGNE to treat tumor cancers. Celgene will acquire 32.7MM or 5.9% of BeiGene's ordinary shares at $4.58 per share. BeiGene to acquire Celgene's commercial operations in China. BeiGene will also license and assume commercial responsibility for Celgene's approved therapies in China.

$CELG {{ '2017-06-19T12:38:44+0000' | timeago}} • Announcement

Pharma firm $CELG said it would present data from various clinical studies evaluating its  investigational agents for the treatment of blood cancer, at the European Hematology Association’s annual meeting to be held in Madrid, Spain, from June 22 to 25. The data will support the role of Celgene’s therapies as the foundation of myeloma research.

$CELG {{ '2017-06-19T10:48:16+0000' | timeago}} • Announcement

$CELG announced results from interim analysis of Magnify, a phase 3b, randomized, open-label, multicenter study of Revlimid (lenalidomide) plus rituximab combination therapy in patients with relapsed or refractory marginal zone lymphoma (MZL). Lymphoma a group of blood cell tumors that develop from lymphocytes (a type of white blood cell).

$CELG {{ '2017-06-14T11:57:50+0000' | timeago}} • Announcement

Celgene International Sarl, a subsidiary of $CELG, announced results from the phase 2a SLE-001 trial evaluating CC-220, its investigational, oral immunomodulatory compound. A trend toward greater improvement with CC-220 treatment compared with placebo in multiple measures of disease activity was observed in patients with lupus.

$CELG {{ '2017-06-06T17:22:32+0000' | timeago}} • Announcement

Pharma companies $CELG and $AGIO said their phase-1 study on leukemia drug Idhifa in patients with relapsed or refractory acute myeloid leukemia and isocitrate dehydrogenase-2 mutation demonstrated an overall response rate of 40.3%. The outcome reinforces the potential for Idhifa as a first-in-class therapy for such patients.

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$CELG {{ '2017-05-22T12:25:38+0000' | timeago}} • Announcement

$CELG announced that its phase III RADIANCE trial, evaluating the efficacy and safety of ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis (RMS), met the primary endpoint in reducing annualized relapse rate (ARR).

$CELG {{ '2017-04-27T14:45:31+0000' | timeago}} • Webcast

$CELG's pipeline includes around 14 unique molecules that are in late-stage development or in proof-of-concept stage development between 2017-2022 and provide opportunity for diversification. $CELG forecasts about $1Bil in revenue from about 10 of these molecules with the other 4 being multi-billion dollar opportunities.

$CELG {{ '2017-04-27T14:30:05+0000' | timeago}} • Webcast

During 1Q17, $CELG saw contraction in the market for OTEZLA, as it saw increased gross-to-net adjustments related to contracts. This gives the company access to up to 100MM insured lives going forward. $CELG also saw minimal drawdown on the inventory. OTEZLA continues to grow market share and gained more than 40% of new patients.

Recent Transcripts

ISRG (Intuitive Surgical, Inc.)
Thursday, October 19 2017 - 8:30pm
MDT (Medtronic plc)
Tuesday, August 22 2017 - 12:00pm
ATHX (Athersys, Inc.)
Wednesday, August 9 2017 - 8:30pm
ARRY (Array BioPharma Inc.)
Wednesday, August 9 2017 - 1:00pm
VCEL (Vericel Corporation)
Wednesday, August 9 2017 - 12:00pm
NVAX (Novavax, Inc.)
Tuesday, August 8 2017 - 8:30pm
OPK (Opko Health, Inc.)
Tuesday, August 8 2017 - 8:30pm
ENDP (Endo International plc)
Tuesday, August 8 2017 - 12:30pm
VRX (Valeant Pharmaceuticals International, Inc.)
Tuesday, August 8 2017 - 12:00pm
ARQL (ArQule Inc.)
Friday, August 4 2017 - 1:00pm
AGN (Allergan plc)
Thursday, August 3 2017 - 12:30pm
EXEL (Exelixis, Inc.)
Wednesday, August 2 2017 - 9:00pm
TRXC (TransEnterix, Inc.)
Wednesday, August 2 2017 - 8:30pm
BTX (BioTime, Inc.)
Wednesday, August 2 2017 - 8:30pm
KTWO (K2M Group Holdings, Inc.)
Tuesday, August 1 2017 - 9:00pm
ABBV (AbbVie Inc.)
Friday, July 28 2017 - 1:00pm
MRK (Merck & Co. Inc.)
Friday, July 28 2017 - 12:00pm
BMY (Bristol-Myers Squibb Company)
Thursday, July 27 2017 - 2:30pm
CELG (Celgene Corporation)
Thursday, July 27 2017 - 1:00pm
GILD (Gilead Sciences Inc.)
Wednesday, July 26 2017 - 8:30pm

AlphaGraphics you may like